The concept of the 'Percent Wasted Patients' in preventive health strategies

被引:11
作者
Cardinal, H [1 ]
Monfared, AAT [1 ]
Dorais, M [1 ]
LeLorier, J [1 ]
机构
[1] Univ Montreal, Ctr Hosp, Dept Pharmacoepidemiol, Montreal, PQ, Canada
关键词
persistence to therapy; waste in health resources; primary prevention;
D O I
10.1002/pds.1148
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of a given preventive treatment, who have discontinued therapy before the time point at which clinical benefits become apparent on the cumulative incidence curves in randomized controlled trials (RCTs) comparing active treatment to placebo. To calculate the PWP, the RCTs that demonstrated the efficacy of the therapy under study must be identified from a MEDLINE search. The point at which the cumulative incidence curves for the main outcome in the experimental and placebo group start diverging is identified and is called the point of visual divergence (PVD). Then, using pharmaceutical claims databases, the percent persistence at the PVD in new users of the therapy is determined. The PWP is then calculated as 100% persistence at PVD. Results For primary prevention with statins, in the province of Quebec, the PWP is 44%. Of 100 patients starting statins for the primary prevention of coronary events, 44 will represent a waste in health resources because they will have discontinued therapy before any clinical benefit can be expected. Conclusions The PWP is a simple measure that can be used by clinicians to select the therapies that need the most reinforcement concerning the importance of persistence. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 6 条
[1]
DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS [J].
ANDRADE, SE ;
WALKER, AM ;
GOTTLIEB, LK ;
HOLLENBERG, NK ;
TESTA, MA ;
SAPERIA, GM ;
PLATT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1125-1131
[2]
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[3]
Adherence with statin therapy in elderly patients with and without acute coronary syndromes [J].
Jackevicius, CA ;
Mamdami, M ;
Tu, JV .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :462-467
[4]
High persistence of statin use in a Danish population: Compliance study 1993-1998 [J].
Larsen, J ;
Andersen, M ;
Kragstrup, J ;
Gram, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) :375-378
[5]
AN ASSESSMENT OF CLINICALLY USEFUL MEASURES OF THE CONSEQUENCES OF TREATMENT [J].
LAUPACIS, A ;
SACKETT, DL ;
ROBERTS, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (26) :1728-1733
[6]
PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307